Hope S. Rugo, MD, a medical oncologist and Director of the Breast Oncology Clinical Trials Program at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502//NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel (Abraxane) compared with nab-paclitaxel or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
Hope S. Rugo, MD, a medical oncologist and director of the Breast Oncology Clinical Trials Program at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502/NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel compared with nab-paclitaxel (Abraxane) or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
At the 4-year median follow-up, the overall results demonstrated inferiority of the ixabepilone arm for both progression-free survival (PFS) and overall survival (OS). Similar results were seen with nab-paclitaxel.
However, a subset analysis showed a trend toward superiority of nab-paclitaxel versus paclitaxel in the triple-negative breast cancer (TNBC) group. In the hormone receptor-positive (HR+) group, investigators found nab-paclitaxel and ixabepilone to be inferior to paclitaxel.
For OS, ixabepilone was inferior, while nab-paclitaxel trended toward inferior in the HR+ subset, although ixabepilone was quite superior for PFS, at 21 months versus 15 months, in the TNBC group.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More